Pharming Group (PHAR) Financials

$10.42 +0.05 (+0.43%)

As of 01:54 PM Eastern

Annual Income Statements for Pharming Group

This table shows Pharming Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Income / (Loss) Attributable to Common Shareholders	-12	-11	14	16	38	41	29
Consolidated Net Income / (Loss)	-12	-11	14	16	38	41	29
Net Income / (Loss) Continuing Operations	-12	-11	14	16	38	41	29
Total Pre-Tax Income	-8.49	-12	15	23	44	52	0.98
Total Operating Income	-8.62	-25	18	14	76	68	44
Total Gross Profit	262	220	188	178	189	165	129
Total Revenue	297	125	206	199	212	190	116
Operating Revenue	297	125	206	199	212	190	116
Total Cost of Revenue	30	25	18	21	23	24	25
Operating Cost of Revenue	35	25	18	21	24	24	25
Other Cost of Revenue	-4.99	-	-	-0.11	-0.07	0.23	-
Total Operating Expenses	273	125	184	167	114	98	47
Selling, General & Admin Expense	71	56	46	37	24	21	14
Marketing Expense	119	-	86	59	52	45	-
Research & Development Expense	83	69	53	70	39	32	33
Total Other Income / (Expense), net	1.89	13	-2.16	8.82	-33	-16	-43
Other Income / (Expense), net	-2.68	13	11	12	-30	-16	-43
Income Tax Expense	3.35	-1.46	1.31	7.08	6.35	12	-28
Basic Earnings per Share	($0.02)	($0.02)	$0.02	$0.03	$0.06	$0.07	$0.04
Weighted Average Basic Shares Outstanding	680.31M	671.07M	656.35M	648.75M	638.82M	-	-
Diluted Earnings per Share	($0.02)	($0.02)	$0.02	$0.02	$0.06	$0.06	$0.04
Weighted Average Diluted Shares Outstanding	680.31M	671.07M	656.35M	648.75M	638.82M	-	-
Weighted Average Basic & Diluted Shares Outstanding	680.31M	671.07M	656.35M	648.75M	638.82M	-	-

No quarterly income statements for Pharming Group are available.

This table details how cash moves in and out of Pharming Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Net Change in Cash & Equivalents	120	-121	14	-71	174	-135	21
Net Cash From Operating Activities	16	-120	16	-31	256	-78	46
Net Cash From Continuing Operating Activities	16	-120	16	-31	256	-78	46
Net Income / (Loss) Continuing Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.98
Depreciation Expense	16	16	13	20	8.31	5.80	7.51
Non-Cash Adjustments To Reconcile Net Income	9.34	-133	-12	-51	248	-81	44
Changes in Operating Assets and Liabilities, net	-9.55	-2.31	14	0.73	-0.02	-2.68	-6.34
Net Cash From Investing Activities	-0.79	-1.44	-1.38	-15	-4.66	-2.65	-4.31
Net Cash From Continuing Investing Activities	-0.79	-1.44	-1.38	-15	-4.66	-2.65	-2.86
Purchase of Property, Plant & Equipment	-0.79	-1.44	-1.38	-11	-4.66	-2.65	-2.86
Net Cash From Financing Activities	105	0.00	0.00	-25	-78	-55	-21
Net Cash From Continuing Financing Activities	105	0.00	0.00	-25	-78	-55	-20
Issuance of Debt	105	0.00	0.00	-	-	-	0.00
Cash Interest Received	5.20	2.88	0.09	0.05	0.72	1.13	-
Cash Income Taxes Paid	16	0.66	1.24	0.00	2.66	5.71	-

No quarterly cash flow statements for Pharming Group are available.

This table presents Pharming Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Total Assets	400	463	426	397	418	256
Total Current Assets	278	316	278	249	263	119
Cash & Equivalents	55	62	207	192	205	74
Accounts Receivable	55	46	28	30	36	29
Inventories, net	56	57	42	27	21	16
Plant, Property, & Equipment, net	7.75	9.69	10	13	12	9.59
Plant, Property & Equipment, gross	7.75	9.69	10	13	12	9.59
Total Noncurrent Assets	110	131	131	106	143	127
Long-Term Investments	0.47	4.31	2.90	1.45	7.12	6.18
Intangible Assets	61	71	75	84	94	79
Noncurrent Deferred & Refundable Income Taxes	31	30	23	-	32	32
Other Noncurrent Operating Assets	18	25	30	21	9.94	9.25
Total Liabilities & Shareholders' Equity	400	463	426	397	418	256
Total Liabilities	179	244	221	204	235	139
Total Current Liabilities	74	78	60	47	77	114
Accounts Payable	67	73	54	42	48	41
Other Current Liabilities	2.95	3.62	3.47	2.42	27	22
Total Noncurrent Liabilities	105	166	161	158	158	24
Long-Term Debt	82	138	133	139	150	0.00
Capital Lease Obligations	27	30	30	18	8.23	4.89
Total Equity & Noncontrolling Interests	221	219	205	193	775	799
Total Preferred & Common Equity	221	219	205	193	183	117
Preferred Stock	489	478	462	455	447	442
Total Common Equity	-268	-260	-258	-262	328	357
Common Stock	7.77	7.67	7.51	7.43	7.31	7.23
Retained Earnings	-275	-265	-256	-273	296	341
Other Equity Adjustments	-0.21	-2.06	-8.74	3.40	25	8.93

No quarterly balance sheets for Pharming Group are available.

This table displays calculated financial ratios and metrics derived from Pharming Group's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	138.44%	-39.38%	3.39%	-6.27%	11.74%	63.78%	0.00%
EBITDA Growth	21.77%	-90.84%	-5.52%	-16.57%	-7.15%	587.34%	0.00%
EBIT Growth	5.89%	-140.70%	15.35%	-44.21%	-12.72%	5,256.41%	0.00%
NOPAT Growth	66.01%	-206.72%	76.98%	-85.60%	23.36%	-95.83%	0.00%
Net Income Growth	-12.26%	-177.14%	-14.52%	-57.62%	-6.93%	41.78%	0.00%
EPS Growth	-12.50%	-184.21%	-17.39%	-58.18%	-8.33%	57.89%	0.00%
Operating Cash Flow Growth	113.24%	-862.56%	151.47%	-111.92%	430.42%	-267.23%	0.00%
Free Cash Flow Firm Growth	95.20%	-722.71%	-138.58%	-66.02%	170.06%	0.00%	0.00%
Invested Capital Growth	-2.82%	8.28%	15.61%	-0.09%	40.14%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	88.09%	176.59%	91.46%	89.37%	88.91%	87.14%	111.51%
EBITDA Margin	1.60%	3.14%	20.77%	22.73%	25.53%	30.72%	7.32%
Operating Margin	-2.90%	-20.35%	8.87%	6.82%	35.94%	35.94%	37.52%
EBIT Margin	-3.80%	-9.64%	14.35%	12.86%	21.61%	27.67%	0.85%
Profit (Net Income) Margin	-3.98%	-8.46%	6.65%	8.04%	17.79%	21.36%	24.67%
Tax Burden Percent	139.44%	87.81%	91.24%	69.31%	85.60%	77.54%	2,916.34%
Interest Burden Percent	75.12%	100.00%	50.79%	90.20%	96.16%	99.55%	100.00%
Effective Tax Rate	0.00%	0.00%	8.76%	30.69%	14.40%	22.46%	-2,816.34%
Return on Invested Capital (ROIC)	-3.76%	-11.34%	11.87%	7.22%	58.53%	113.95%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	6.01%	-24.41%	16.92%	5.36%	62.61%	117.45%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-1.62%	6.36%	-4.99%	-3.92%	-53.74%	-103.80%	0.00%
Return on Equity (ROE)	-5.38%	-4.98%	6.88%	3.31%	4.80%	10.15%	0.00%
Cash Return on Invested Capital (CROIC)	-0.90%	-19.29%	-2.62%	7.31%	25.11%	-86.05%	0.00%
Operating Return on Assets (OROA)	-2.62%	-2.70%	7.17%	6.27%	13.60%	20.53%	0.00%
Return on Assets (ROA)	-2.74%	-2.37%	3.32%	3.92%	11.19%	15.85%	0.00%
Return on Common Equity (ROCE)	6.46%	6.09%	-9.00%	0.22%	2.09%	4.54%	0.00%
Return on Equity Simple (ROE_SIMPLE)	-5.36%	-4.82%	6.68%	8.29%	20.58%	34.55%	0.00%
Net Operating Profit after Tax (NOPAT)	-6.03	-18	17	9.40	65	53	1,269
NOPAT Margin	-2.03%	-14.24%	8.09%	4.73%	30.77%	27.87%	1,094.35%
Net Nonoperating Expense Percent (NNEP)	-9.77%	13.07%	-5.06%	1.87%	-4.08%	-3.50%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-1.83%	-4.59%	4.52%	-	-	-	-
Cost of Revenue to Revenue	10.23%	20.23%	8.54%	10.57%	11.06%	12.73%	21.90%
SG&A Expenses to Revenue	23.77%	44.83%	22.38%	18.59%	11.35%	11.16%	12.07%
R&D to Revenue	27.98%	55.29%	25.55%	35.38%	18.15%	16.74%	28.51%
Operating Expenses to Revenue	91.72%	100.12%	89.65%	83.87%	53.83%	51.46%	40.58%
Earnings before Interest and Taxes (EBIT)	-11	-12	30	26	46	53	0.98
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.77	3.91	43	45	54	58	8.49
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.04	0.03	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.06	0.04	0.00
Price to Revenue (P/Rev)	2.27	6.02	3.48	2.87	0.06	0.06	0.09
Price to Earnings (P/E)	0.00	0.00	52.33	35.70	0.36	0.27	0.38
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	1.91%	2.80%	276.07%	372.51%	262.73%
Enterprise Value to Invested Capital (EV/IC)	7.70	8.17	7.52	7.63	3.13	4.61	0.00
Enterprise Value to Revenue (EV/Rev)	4.10	10.67	5.50	4.99	1.92	2.26	0.00
Enterprise Value to EBITDA (EV/EBITDA)	255.69	340.03	26.48	21.95	7.52	7.34	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	38.31	38.78	8.89	8.15	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	67.96	105.55	6.24	8.09	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	76.82	0.00	71.96	0.00	1.59	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	104.29	14.56	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.49	0.77	0.80	0.83	0.21	0.07	0.00
Long-Term Debt to Equity	0.49	0.77	0.80	0.82	0.20	0.01	0.00
Financial Leverage	-0.27	-0.26	-0.29	-0.73	-0.86	-0.88	0.00
Leverage Ratio	1.96	2.10	2.07	0.84	0.43	0.32	0.00
Compound Leverage Factor	1.47	2.10	1.05	0.76	0.41	0.32	0.00
Debt to Total Capital	33.10%	43.43%	44.37%	45.23%	17.12%	6.55%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.53%	0.22%	5.98%	0.00%
Long-Term Debt to Total Capital	33.10%	43.43%	44.37%	44.70%	16.90%	0.57%	0.00%
Preferred Equity to Total Capital	147.99%	123.72%	125.67%	129.24%	47.84%	51.70%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-81.09%	-67.14%	-70.04%	-74.47%	35.04%	41.75%	0.00%
Debt to EBITDA	22.95	42.92	3.82	3.53	2.95	0.96	0.00
Net Debt to EBITDA	11.32	26.04	-1.11	-0.76	-0.98	-0.42	0.00
Long-Term Debt to EBITDA	22.95	42.92	3.82	3.48	2.92	0.08	0.00
Debt to NOPAT	-18.12	-9.46	9.81	16.95	2.45	1.06	0.00
Net Debt to NOPAT	-8.94	-5.74	-2.84	-3.64	-0.82	-0.46	0.00
Long-Term Debt to NOPAT	-18.12	-9.46	9.81	16.75	2.42	0.09	0.00
Altman Z-Score	2.56	1.84	2.42	2.04	2.43	3.35	0.00
Noncontrolling Interest Sharing Ratio	219.95%	222.17%	230.80%	93.26%	56.50%	55.33%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	3.77	4.06	4.65	5.33	3.43	1.05	0.00
Quick Ratio	1.49	1.38	3.94	4.74	3.14	0.90	0.00
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.45	-30	-3.67	9.51	28	-40	0.00
Operating Cash Flow to CapEx	2,007.72%	-8,337.23%	1,141.79%	-284.25%	5,501.14%	-2,929.09%	1,622.92%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.69	0.28	0.50	0.49	0.63	0.74	0.00
Accounts Receivable Turnover	5.89	3.38	7.14	6.04	6.55	6.58	0.00
Inventory Turnover	0.54	0.51	0.50	0.87	1.26	1.49	0.00
Fixed Asset Turnover	34.08	12.41	17.42	15.63	19.45	19.80	0.00
Accounts Payable Turnover	0.44	0.40	0.36	0.47	0.53	0.59	0.00
Days Sales Outstanding (DSO)	62.01	108.02	51.12	60.46	55.71	55.49	0.00
Days Inventory Outstanding (DIO)	675.07	717.25	723.64	420.64	290.66	245.07	0.00
Days Payable Outstanding (DPO)	835.04	919.25	1,007.36	782.31	686.70	614.01	0.00
Cash Conversion Cycle (CCC)	-97.96	-93.98	-232.59	-301.21	-340.33	-313.46	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	158	163	150	130	130	93	0.00
Invested Capital Turnover	1.85	0.80	1.47	1.53	1.90	4.09	0.00
Increase / (Decrease) in Invested Capital	-4.58	12	20	-0.11	37	93	0.00
Enterprise Value (EV)	1,218	1,331	1,131	992	408	428	0.00
Market Capitalization	675	750	716	571	14	11	11
Book Value per Share	($0.40)	($0.40)	($0.39)	($0.41)	$0.51	$396.61	$0.00
Tangible Book Value per Share	($0.49)	($0.50)	($0.51)	($0.54)	$0.37	$308.36	$0.00
Total Capital	330	387	368	352	935	855	0.00
Total Debt	109	168	163	159	160	56	0.00
Total Long-Term Debt	109	168	163	157	158	4.89	0.00
Net Debt	54	102	-47	-34	-53	-25	0.00
Capital Expenditures (CapEx)	0.79	1.44	1.38	11	4.66	2.65	2.86
Debt-free, Cash-free Net Working Capital (DFCFNWC)	150	177	10	12	-18	-18	0.00
Debt-free Net Working Capital (DFNWC)	205	238	218	205	188	56	0.00
Net Working Capital (NWC)	205	238	218	203	186	5.18	0.00
Net Nonoperating Expense (NNE)	5.81	-7.21	2.96	-6.60	28	12	1,240
Net Nonoperating Obligations (NNO)	-63	-56	-54	-63	-645	-706	0.00
Total Depreciation and Amortization (D&A)	16	16	13	20	8.31	5.80	7.51
Debt-free, Cash-free Net Working Capital to Revenue	50.37%	141.71%	4.98%	6.24%	-8.37%	-9.50%	0.00%
Debt-free Net Working Capital to Revenue	68.86%	191.25%	105.92%	102.86%	88.80%	29.65%	0.00%
Net Working Capital to Revenue	68.86%	191.25%	105.92%	101.91%	87.84%	2.73%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	($0.02)	$0.02	$0.00	$0.05	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	680.31M	671.07M	656.35M	0.00	638.82M	0.00	0.00
Adjusted Diluted Earnings per Share	($0.02)	($0.02)	$0.02	$0.00	$0.05	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	680.31M	671.07M	656.35M	0.00	638.82M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	680.31M	671.07M	656.35M	0.00	638.82M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-6.03	-18	17	9.40	65	53	30
Normalized NOPAT Margin	-2.03%	-14.24%	8.09%	4.73%	30.77%	27.87%	26.27%
Pre Tax Income Margin	-2.86%	-9.64%	7.29%	11.60%	20.78%	27.55%	0.85%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for Pharming Group are available.

Frequently Asked Questions About Pharming Group's Financials

When does Pharming Group's financial year end?

According to the most recent income statement we have on file, Pharming Group's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Pharming Group's net income changed over the last 6 years?

Pharming Group's net income appears to be on a downward trend, with a most recent value of -$11.84 million in 2024, falling from $28.60 million in 2018. The previous period was -$10.55 million in 2023. Check out Pharming Group's forecast to explore projected trends and price targets.

What is Pharming Group's operating income?

Pharming Group's total operating income in 2024 was -$8.62 million, based on the following breakdown:

Total Gross Profit: $261.80 million
Total Operating Expenses: $272.60 million

How has Pharming Group revenue changed over the last 6 years?

Over the last 6 years, Pharming Group's total revenue changed from $115.93 million in 2018 to $297.20 million in 2024, a change of 156.4%.

How much debt does Pharming Group have?

Pharming Group's total liabilities were at $178.92 million at the end of 2024, a 26.7% decrease from 2023, and a 29.2% increase since 2019.

How much cash does Pharming Group have?

In the past 5 years, Pharming Group's cash and equivalents has ranged from $54.94 million in 2024 to $207.34 million in 2022, and is currently $54.94 million as of their latest financial filing in 2024.

How has Pharming Group's book value per share changed over the last 6 years?

Over the last 6 years, Pharming Group's book value per share changed from 0.00 in 2018 to -0.40 in 2024, a change of -39.9%.

Related Companies

This page (NASDAQ:PHAR) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Financials

Frequently Asked Questions About Pharming Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Financials

Annual Income Statements for Pharming Group

Quarterly Income Statements for Pharming Group

Annual Cash Flow Statements for Pharming Group

Quarterly Cash Flow Statements for Pharming Group

Annual Balance Sheets for Pharming Group

Quarterly Balance Sheets for Pharming Group

Annual Metrics And Ratios for Pharming Group

Quarterly Metrics And Ratios for Pharming Group

Frequently Asked Questions About Pharming Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools